glutathione synthetase gene REGULATION OF GLUTATHIONE SYNTHESIS -

FDA 503A Category 2 (April 2026) On April 15, 2026, the FDA published a 503A bulks list update

Scarvie KM, Ballantyne AO, Trauner DA (1996) Visuomotor performance in children with infantile nephropathic cystinosis

Beyond their deliberate use in treating brain disorders, nanomaterials may also access the CNS unintentionally, either via systemic circulation following peripheral therapeutic applications or through inhalation exposure from the environment

[12] Not consuming enough folate can lead to folate deficiency

In total, nine treated patients had significantly reduced discomfort and improved tear volume production, even 28 days following treatment